PolyPid Ltd. (PYPD) NASDAQ
4.87
-0.2(-3.94%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.87
-0.2(-3.94%)
Currency In USD
Address
18 Hasivim Street
Petah Tikva, 4959376
Israel
Phone
972 7 4719 5700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
57
First IPO Date
June 26, 2020
| Name | Title | Pay | Year Born |
| Dalit Hazan | Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs | 394,806 | 1972 |
| Dikla Czaczkes Akselbrad | Chief Executive Officer & Director | 558,344 | 1973 |
| Jonny Missulawin | Chief Financial Officer | 270,558 | 1987 |
| Ori Warshavsky | Chief Operating Officer - US | 418,497 | 1979 |
| Nurit Tweezer-Zaks | Chief Medical Officer | 0 | 1967 |
| Jean-Marc Hagai | Chief Commercial Officer | 0 | N/A |
| Maria Rubin | Executive Vice President of Operations | 0 | N/A |
| Rivi Lev-ari | Vice President of Human Resource | 0 | N/A |
| Tal Vilnai | General Counsel & Corporate Secretary | 0 | N/A |
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.